| Galantamine extended release. | |
| | |
MedLine Citation:
|
PMID: 16863272 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Galantamine inhibits acetylcholinesterase (AChE) to slow acetylcholine hydrolysis, and may also modulate presynaptic nicotinic receptor activation, thereby increasing neurotransmitter concentrations in the synaptic cleft.black triangle Once-daily galantamine extended release (ER) 24 mg and twice-daily galantamine immediate release (IR) 12 mg are bioequivalent in terms of the area under the plasma concentration-time curve from time 0 to 24 hours and steady-state minimum plasma concentration.black triangle Primary endpoints indicated a significantly greater effect of galantamine ER on cognitive performance than placebo, with efficacy similar to galantamine IR, in a randomised, double-blind trial. While galantamine ER did not show a significant effect on the coprimary endpoint of global change, neither did galantamine IR in this study. Exploratory post hoc analyses of global change correcting for study centre and prognostic factors associated with response (baseline Mini-Mental State Examination, Alzheimer's Disease Assessment Scale cognitive score, prior cholinomimetic use) indicated nominal significance in the galantamine ER treatment arm. Secondary endpoints indicated an improvement in activities of daily living and memory- and nonmemory-dependent measures of cognitive performance, but not in measures of behaviour or dichotomised rating of global change. Adverse events occurred in similar proportions of galantamine ER, galantamine IR and placebo recipients. |
| | |
Authors:
|
Dean M Robinson; Greg L Plosker |
Publication Detail:
|
Type: Evaluation Studies; Journal Article |
Journal Detail:
|
Title: CNS drugs Volume: 20 ISSN: 1172-7047 ISO Abbreviation: CNS Drugs Publication Date: 2006 |
Date Detail:
|
Created Date: 2006-07-25 Completed Date: 2006-09-19 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 9431220 Medline TA: CNS Drugs Country: New Zealand |
Other Details:
|
Languages: eng Pagination: 673-81; discussion 682-3 Citation Subset: IM |
Affiliation:
|
Adis International Limited, Auckland, New Zealand. demail@adis.co.nz |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Alzheimer Disease
/
drug therapy* Cholinesterase Inhibitors / administration & dosage*, pharmacology Clinical Trials as Topic Drug Administration Routes Drug Administration Schedule Galantamine / administration & dosage*, pharmacology Humans Inhibitory Concentration 50 |
| Chemical | |
Reg. No./Substance:
|
0/Cholinesterase Inhibitors; 357-70-0/Galantamine |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Discontinuation syndrome associated with paroxetine in depressed patients: a retrospective analysis ...
Next Document: Pregabalin: in the treatment of generalised anxiety disorder.